Distretto Tecnologico Sicilia Micro E Nano Sistemi S.c.a.r.l.

Universita' Degli Studi Di Palermo

Novagenit S.r.l.

Mero S.r.l.

Nemysis Limited

Consiglio Nazionale Delle Ricerche

Università Degli Studi Di Catania

Gaetano Giammona

Giovanna Pitarresi

Fabio Salvatore Palumbo

Salvatore Cuzzocrea

Santa Viola

Anna Rita Blanco

Emanuela Fabiola Craparo

Patrizia Guarneri

Emanuela Esposito

Grazia Maria Letizia Consoli

Mariano Licciardi

Gennara Cavallaro

Salvatore Papasergi

Patrizia Saladino

Edgardo Cremascoli

Irene Ceidda

Maria Luisa Bondi'

Guiseppe Granata

Clara La Marca

Enzo Meani

Carlo Luca Romano

Melchiorre Cervello

Roberto Puleio

Guido Ruggero Loria

Maria Luisa Bondi′

Irene Deidda

Stefano Puleo

Giuseppe Granata

Carlo Luca Romano′

Antonina Azzolina

Clara La Marco

Filippo Drago

Maria Luisa Bondi

Carlo Luca Romano'

Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.

Nanostructured formulations for the delivery of silibinin and other active ingredients for treating ocular diseases

Described herein are loaded nanoparticles of Sorafenib (Sorafenib PBB) or Sorafenib derivatives (Sorafenib PBB derivatives), wherein the nanoparticles are polymeric PBB nanoparticles, (PHEA-BIB-pButMA, &#x3b1;,&#x3b2;-poly(N-2-hydroxyethyl)-co-{N-2-ethylene-[2-(poly(butylmethacrylate)-isobutyrate]}-D, L-aspartamide, as well as a method for obtaining them. Also described herein are a controlled release formulation of Sorafenib or Sorafenib, derivatives that include Sorafenib PBB or Sorafenib PBB derivatives, and to the use of the formulation in the treatment of tumor diseases of the kidney, liver, thyroid, colon, breast, pancreas, lungs and/or recurrent glioblastoma.

Nanoparticles for controlled release of Sorafenib and Sorafenib derivatives

The present invention relates to a composition comprising hydrogels from functionalized hyaluronic acid derivatives, said hydrogels loaded with exogenous enzymes selected in the group consisting of prolyl endopeptidase (PEP) and endoprotease (EP) intended for the oral treatment of celiac disease. Specifically, this invention concerns a one-pot methodology useful to prepare methacrylic derivatives of hyaluronic acid, through the formation of a specific active group on hydroxyl groups of hyaluronic acid, the subsequent substitution of the inserted active group with ethylenediamine and finally, the reaction with methacrylic anhydride. The obtained methacrylic hyaluronic acid derivatives are used to prepare hydrogels through irradiation and loaded with exogenous enzymes selected in the group consisting of prolyl endopeptidase (PEP) and endoprotease (EP). The ability of prepared hydrogels to allow the enzyme release, as active form in simulated gastrointestinal fluids is proved.

Hydrogels of methacrylic hyaluronic acid derivatives for oral enzyme therapy in celiac disease

In this invention a two steps procedure is described useful to insert functional groups to the hyaluronic acid (HA), through the formation, in organic solvent, of a particular active group on hydroxyl groups of HA and subsequent substitution, on the inserted active group, with a pendant portion containing at least in its terminal portion a nucleophilic functional group, NH&#x2014;R. The group inserted by nucleophilic substitution can contain in another its terminal portion a further nucleophilic functional group, in a way to be easily exploitable to further chemical functionalizations, such as an example to obtain the methacrylation of HA functional groups, to obtain photocrosslinkable derivatives. Both direct derivatives of the proposed process and those obtained by the further functionalization can be employed to produce hydrogels.

Method to produce hyaluronic acid functionalized derivatives and formation of hydrogels

The present invention relates to hydrogels based on hyaluronic acid based derivatives, that are more resistant than hyaluronic acid alone towards chemical and enzymatic degradation and are endowed with a mix of chemical and mechanical properties such that they are of optimal use in several surgeries, for instance for injection in bone fractures or cavities and for the production of coatings of prostheses in orthopedic surgery, as fillers in cosmetic and maxillo-facial surgery, as anti-adhesion barrier in the prevention of postoperative adhesions in abdominal and abdominal/pelvic surgery, and in general surgery. These hydrogels can be loaded with several different kinds of compounds having pharmacological and biological activity, that are then released from the hydrogel in the site of intervention.

Hyaluronic acid based hydrogel and use thereof in surgery

Method to produce hyaluronic acid functionalized derivatives and formation of hydrogels thereof

The present invention relates to hydrogels endowed with antibacterial properties, to be used for injection in damaged bones or in the production of antibacterial coatings of prostheses for implant in the human or animal body, obtained by loading with antibacterial agents hydrogels formed by derivatives of hyaluronic acid; the invention also relates to a kit of parts for producing the antibacterial hydrogels.

Antibacterial hydrogel and use thereof in orthopedics

Growing community of inventors

Palermo, Italy

Gaetano Giammona